Over the past several years, advanced heart failure patients who have not responded to medical therapy have been given new hope, and are surviving longer with implanted left ventricular assist devices (LVADs). Although echocardiography is recommended for each phase of care for patients with LVADs, there has been limited published data and no formal guidance for the use of echocardiography in this growing patient population. In an effort to fill this gap, a new document, Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography, will appear in the August 2015 issue of the Journal of the American Society of Echocardiography (JASE).

Triple therapy is no better than dual antiplatelet therapy in preventing major adverse cardiac events in older patients with atrial fibrillation who had a heart attack treated with angioplasty, according to a new study. The study, published in the Journal of the American College of Cardiology, also found that triple therapy resulted in more complications.

Jeff Zagoudis, associate editor of the Scranton Gillette Communications’ Healthcare Group publications Imaging Technology News (ITN) and Diagnostic and Interventional Cardiology (DAIC), was recently honored by the American Society of Business Publication Editors (ASBPE) as one of its three Young Leader Scholars.

Specific cardiovascular risk factors are associated with smaller regional brain volumes that may be early indicators of Alzheimer’s disease and dementia, according to a study published online in the journal Radiology. Those factors include alcohol consumption, smoking, obesity and diabetes.

Biotronik announced CE approval of 3 Tesla (T) magnetic resonance imaging (MRI) scanning with exclusion zone for its two latest generations of pacemakers. The company now offers both implantable cardioverter-defibrillators (ICDs) and pacemakers approved for 3T scans.

Sunshine Heart announced plans to commence a first-in-human study using its novel C-Pulse transcutaneous energy transmission (TET) system and a new, smaller implantable pump in quarter three 2016.

Pie Medical Imaging announced the release of CAAS IntraVascular 2.0, the dedicated software for analysis of intravascular ultrasound (IVUS), near-infrared spectroscopy (NIRS)-IVUS and optical coherence tomography (OCT) datasets. This new release contains an optimized OCT analysis and the in-depth analysis of NIRS-IVUS datasets. Data can be imported easily from the console or picture archiving and communication system (PACS) into the study list, which provides a clear overview of your data. CAAS IntraVascular has U.S. Food and Drug Administration (FDA) 510(k) clearance for both IVUS and OCT.

European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic

According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents accounted for a significant portion of the European markets for interventional cardiology devices in 2014. The advent of drug-eluting stents has driven the interventional cardiology market beyond expectations, as these devices have managed to increase the size of the market by virtue of their relatively high average selling price (ASP). New developments in drug-eluting stents such as biodegradable materials are expected to keep the market competitive despite safety concerns regarding late stent thrombosis.

Colegio Argentino de Cardioangiólogos Intervencionistas

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now